Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Theravance

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Double asthma approval in Japan lifts SkyePharma

Regulatory wins for company’s commercial partners GSK and Kyorin

J&J seeks European digital health entrepreneurs

Digital health mentor programme will culminate in €50,000 challenge

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

US FDA approves Vibativ for lung infection caused by MRSA

Theravance’s drug backed to treat hospital-acquired bacterial pneumonia

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

New data backs J&J’s ibrutinib efficacy in B cell cancers

Phase II results showcased at European Hematology Association meeting

- PMLiVE

J&J wins silver for nursing campaign at 2013 North America Effie Awards

‘Healing a profession from the inside out’ designed to acknowledge nursing skills

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

- PMLiVE

Johnson & Johnson launches first corporate campaign for decade

Campaign intended to reinforce company values to consumer

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

- PMLiVE

GSK wins US approval for Seretide successor Breo Ellipta

FDA gives green light to COPD combination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links